2022 American Transplant Congress
Valganciclovir for the Prevention of CMV After Treatment of Rejection with Anti-Lymphocyte Depleting Antibodies in Kidney Transplant Recipients
University Health, San Antonio, TX
*Purpose: To evaluate efficacy and safety of valganciclovir for prevention of cytomegalovirus (CMV) after treatment of rejection with anti-lymphocyte depleting antibodies (ALA).*Methods: This single-center retrospective…2022 American Transplant Congress
The Trajectory of Donor-Derived Cell-Free DNA (dd-cfDNA) Complements the Baseline Measurements in Heart Transplant Surveillance for Rejection
*Purpose: Changes in dd-cfDNA levels over time may identify patients with evolving alloimmune injury, providing complementary information to the donor fraction. We explored the dd-cfDNA…2022 American Transplant Congress
Deep Phenotyping Methods Highlight Recipient-Derived CD16+ NK and CD16+ Monocyte Infiltration During Kidney Transplant Rejection
*Purpose: How the immune system participates to kidney transplant rejection has not been fully elucidated. Single-cell (sc) genomics techniques are revolutionizing our ability to characterize…2022 American Transplant Congress
Impact of ATG Dose Reduction on Kidney Transplant Outcomes During the Covid-19 Pandemic
*Purpose: During the COVID-19 pandemic, many transplant centers modified induction immunosuppression regimens. Beginning December 2020, our center reduced anti-thymocyte globulin (ATG) protocol dosing by up…2022 American Transplant Congress
Circulating and Intragraft Donor (HLA)-Specific B Cells Drive Allograft Rejection After Kidney Transplantation
*Purpose: Besides donor-specific antibodies (DSA), circulating donor(HLA)-specific memory B cells (mBc) have also shown to play a deleterious role driving antibody-mediated rejection (ABMR) in kidney…2022 American Transplant Congress
Urinary Cell mRNA Profile Diagnosis of Borderline TCMR in Kidney Allografts
1Nephrology, Weill Cornell-NYPH, New York, NY, 2Pathology, Weill Cornell-NYPH, New York, NY
*Purpose: Borderline T cell-mediated rejection (BR) is associated with inferior outcomes. In the multicenter CTOT-04 study, we discovered and validated a urinary cell three-gene signature…2022 American Transplant Congress
Synergistic Effect of CXCR5+CD8+ TAb-supp Cell Adoptive Cell Therapy and mTOR Inhibition (but Not Calcineurin Inhibition) in Suppressing Alloantibody Following Kidney Transplant in Mice
*Purpose: We have reported that CXCR5+CD8+TAb-supp cells mediate suppression of alloantibody (alloAb) production and prolong graft survival in both hepatocellular and kidney transplant (KTx) mouse…2022 American Transplant Congress
Significance of Gene Polymorphism on Infectious Complications and Rejection After Liver Transplantation
*Purpose: Clinical application of gene polymorphism is a key of precision medicine in the field of organ transplantation. Hiroshima group reported significance of Fc-gamma receptor…2022 American Transplant Congress
Assessing Proportion of Days Covered (PDC) of Mycophenolate (MCP) Prescriptions in Post Kidney Transplant (KT) Recipients as a Predictor of Clinical Outcomes
*Purpose: Nonadherence to medications following KT is a risk factor for adverse outcomes. PDC is an objective measure of adherence obtained through retail prescription records…2022 American Transplant Congress
Impact of Sars-CoV-2 Vaccination on Donor-Derived Cell Free DNA Levels in Renal Transplant Recipients
Columbia University Irving Medical Center, New York, NY
*Purpose: COVID-19 poses a disproportionate threat to renal transplant recipients (RTR), who are chronically immunosuppressed. Studies have indicated a 16% mortality rate compared to
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 172
- Next Page »